Fig. 2From: Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancerInternal validation of model. Kaplan Meier OS and PFS curves from IMpassion130 trial and model-generated OS and PFS curves are shown. Modelled clinical outcomes showed agreement with empirical data from the IMpassion130 trial in terms of median OS and PFS and 2-year OSBack to article page